Company Overview and News

Hong Kong stocks fall, energy shares weigh

2018-07-17 theedgemarkets
SHANGHAI (July 17): Hong Kong stocks ended lower on Tuesday, dragged by energy firms following a sharp decline in crude oil prices.
1336 GGDVF GGDVY 0270 CEO 1044

China and Hong Kong stocks slide, with Shanghai Composite Index declining to two-year low

2018-06-25 scmp
Cut in reserve requirement ratio announced on Sunday by People’s Bank of China ‘doesn’t signal a shift in monetary policies’, as the central bank ‘continues to focus on deleveraging’, say analysts

China, Hong Kong stocks wobble on trade war fears

2018-06-21 thehindubusinessline
China and Hong Kong shares reversed earlier gains to slide on Thursday, as concerns over a trade spat between China and the United States weighed on sentiment.
1336 CGHLY JINDALSAW 0914 500378 CGHOF CEO 1088 0384

Chinese tech stocks surge after Nasdaq closes at all-time high

2018-06-05 scmp
Mainland Chinese and Hong Kong stocks closed higher on Tuesday, bolstered by the technology sector, after Apple, Amazon and Microsoft touched fresh records helping to push the Nasdaq to an all-time closing high overnight.
1336 2628 0700 SOTGY LFC 2382 SNPTF AACAY AACAF

Moody’s raises view on China life insurers as regulatory tightening cuts risk

2018-06-05 scmp
A government crackdown on the practice of issuing short-term policies for financial gain is improving the industry’s creditworthiness, the agency says
1336 2628 CHIB 2601 LFC CKGOY

China’s high-flying big-cap stocks hit as PBOC raises borrowing costs

2018-03-22 scmp
The SSE 50 Index is set for the steepest decline in three weeks after China’s central bank raised 7-day reverse repo rates

China, Hong Kong stocks rise as developers rally on stellar profits

2018-03-21 thehindubusinessline
Stocks in China and Hong Kong rallied on Wednesday, led by real estate firms, after developers posted stellar profits for 2017.
CRBJY 1336 1109 CRBJF 2007

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...